Indinavir

• UNSPSC Description:

  Indinavir (MK-639 free base) is an orally active and selective HIV-1 protease inhibitor with a Ki of 0.54 nM for PR. Indinavir exhibits anticancer activity by inhibiting the activation of MMPs-2 hydrolysis, anti-angiogenesis and inducing apoptosis. Indinavir is also a SARS-CoV 3CLpro inhibitor[1][2][3][4].

• Target Antigen:

  Apoptosis; HIV; HIV Protease; MMP; SARS-CoV

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Apoptosis;Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Inflammation/Immunology; Cancer

• Assay Protocol:

  https://www.medchemexpress.com/indinavir.html

• Purity:

  99.96

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C([C@@H](C[C@H](O)CN(CCN(CC1=CN=CC=C1)C2)[C@@H]2C(NC(C)(C)C)=O)CC3=CC=CC=C3)N[C@H]4C(C=CC=C5)=C5C[C@H]4O

• Molecular Weight:

  613.79

• References & Citations:

  [1]Chavan S, et al. The HIV protease inhibitor Indinavir inhibits cell-cycle progression in vitro in lymphocytes of HIV-infected and uninfected individuals. Blood. 2001 Jul 15;98(2):383-9.|[2]Esposito V, et al. Evaluation of antitumoral properties of the protease inhibitor indinavir in a murine model of hepatocarcinoma. Clin Cancer Res. 2006 Apr 15;12(8):2634-9.|[3]Liu F, et al. Kinetic, stability, and structural changes in high-resolution crystal structures of HIV-1 protease with drug-resistant mutations L24I, I50V, and G73S. J Mol Biol. 2005 Dec 9;354(4):789-800. |[4]Hall DC Jr, et al. A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Med Infect Dis. 2020 May-Jun;35:101646.Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20.|Antiviral Res. 2022 Nov 10;105463.|Nat Commun. 2020 Sep 4;11(1):4417.|Toxicol In Vitro. 2023 Sep 1;105689.|bioRxiv. 2020 Apr.|Front Pharmacol. 2021 Apr 12;12:634097.|Int J Antimicrob Agents. 2019 Dec;54(6):814-819.|Signal Transduct Target Ther. 2021 May 29;6(1):212.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  150378-17-9